Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AXERT® 12.5mg Time vs Intensity Migraine Study (AIMS): An Open-label Multicenter Trial to Evaluate the Efficacy of Almotriptan Malate (AXERT®) 12.5 Milligram Intervention at Onset of Migraine Pain

NCT00212823 is registered in ClinicalTrials.gov with Ortho-McNeil Neurologics, Inc. as lead sponsor.

NCT NCT00212823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00212823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AXERT® 12.5mg Time vs Intensity Migraine Study (AIMS): An Open-label Multicenter Trial to Evaluate the Efficacy of Almotriptan Malate (AXERT®) 12.5 Milligram Intervention at Onset of Migraine Pain
Lead sponsor
Ortho-McNeil Neurologics, Inc.
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2004
Completion date
February 28, 2005
Enrollment
1,450 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

migraine